{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T14:02:30Z","timestamp":1756994550038,"version":"3.40.5"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,30]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Hodgkin lymphoma (HL) is a rare lymphoproliferative disorder that occurs in about 10% of all cancer cases. Human immunodeficiency virus (HIV) is associated with an increased occurrence of a wide range of cancers, including HL due to progressive immunosuppression and co-infection with oncogenic viruses. However, the aim of this systematic review is to obtain evidence about the impact of the HIV infection in HL individuals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We will obtain studies through PubMed, Embase, CINAHL, LILACS, CENTRAL, Web of Science, Scopus, Cochrane Library, and Google Scholar databases. The inclusion criteria will be observational studies (sectional, cohort, and case-control) that describe the impact of the HIV infection in HL individuals. Outcomes of interest include mortality, prevalence, causes of hospitalization, time between HIV diagnosis and HL diagnosis in days, comorbidities (systemic hypertension, diabetes mellitus, metabolic syndrome, others), T CD4\u2005+\u2005cells\/mm<jats:sup>3<\/jats:sup> at HIV diagnosis and at HL diagnosis, viral load (log10 copies\/mL) at HL diagnosis, and history of treatment abandon. Two reviewers, independently, will extract the data from each included study. Meta-analysis will then be carried out using fixed-effects or random-effects model, using the mean difference for continuous outcomes and the relative risk for dichotomous outcomes. Risk of bias will be assessed using the Newcastle\u2013Ottawa Scale. The quality of evidence for each outcome will be assessed using Grading of Recommendations Assessment, Development and Evaluation methodology. Review Manager V.5.3.5 will be used for synthesis and subgroup analysis. To assess heterogeneity, we will compute the <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup> statistics. Additionally, a quantitative synthesis will be performed if the included studies are sufficiently homogenous.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ethics and dissemination:<\/jats:title>\n            <jats:p>This study will be a review of the published data, and thus it is not necessary to obtain ethical approval. The findings of this systematic review will be published in a peer-reviewed journal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PROSPERO registration number:<\/jats:title>\n            <jats:p>CRD42021289520<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000030765","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T13:03:14Z","timestamp":1664542994000},"page":"e30765","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Impact of the HIV infection in Hodgkin lymphoma individuals: A protocol for systematic review and meta analysis"],"prefix":"10.1097","volume":"101","author":[{"given":"Raissa Bila Cabral","family":"Fagundes","sequence":"first","affiliation":[{"name":"Instituto de Ensino, Pesquisa e Inova\u00e7\u00e3o, Liga Contra o C\u00e2ncer, Natal, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leno Goes","family":"Delgado de Mederios","sequence":"additional","affiliation":[{"name":"Instituto de Ensino, Pesquisa e Inova\u00e7\u00e3o, Liga Contra o C\u00e2ncer, Natal, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaxsell Thiago","family":"Barros de Souza","sequence":"additional","affiliation":[{"name":"Instituto de Ensino, Pesquisa e Inova\u00e7\u00e3o, Liga Contra o C\u00e2ncer, Natal, Brazil"},{"name":"Department of Pharmacy, Health Sciences Center, Federal University of Rio Grande do Norte (UFRN), Natal, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Isabel","family":"Oliveira da Silva","sequence":"additional","affiliation":[{"name":"Instituto de Ensino, Pesquisa e Inova\u00e7\u00e3o, Liga Contra o C\u00e2ncer, Natal, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matheus Jose Barbosa","family":"Moreira","sequence":"additional","affiliation":[{"name":"Department of Medicine, Health Sciences Center, Federal University of Rio Grande do Norte (UFRN), Natal, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina Cola\u00e7o","family":"Villarrim","sequence":"additional","affiliation":[{"name":"Department of Haematology, Liga Contra o C\u00e2ncer, Natal, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irami","family":"Ara\u00fajo-Filho","sequence":"additional","affiliation":[{"name":"Department of Medicine, Health Sciences Center, Federal University of Rio Grande do Norte (UFRN), Natal, Brazil"},{"name":"Health Sciences Postgraduate Program, Federal University of Rio Grande do Norte (UFRN), Natal, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4105-7535","authenticated-orcid":false,"given":"Kleyton Santos","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Instituto de Ensino, Pesquisa e Inova\u00e7\u00e3o, Liga Contra o C\u00e2ncer, Natal, Brazil"},{"name":"Health Sciences Postgraduate Program, Federal University of Rio Grande do Norte (UFRN), Natal, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br J Cancer"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.seminhematol.2016.05.002","article-title":"Hodgkin lymphoma in the elderly, pregnant, and HIV-infected","volume":"53","author":"Bachanova","year":"2016","journal-title":"Semin Hematol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"e2100163","DOI":"10.1200\/GO.21.00163","article-title":"HIV and Hodgkin Lymphoma survival: a prospective study in Botswana","volume":"8","author":"Moahi","year":"2022","journal-title":"JCO Glob Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00277-018-3533-0","article-title":"Hodgkin lymphoma at Groote Schuur Hospital, South Africa: the effect of HIV and bone marrow infiltration","volume":"98","author":"Swart","year":"2019","journal-title":"Ann Hematol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1055-9965.EPI-13-0865","article-title":"Prevalence of HIV infection among US Hodgkin lymphoma cases","volume":"23","author":"Shiels","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/QAI.0b013e3181b327ca","article-title":"A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals","volume":"52","author":"Shiels","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/cncr.29066","article-title":"Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study","volume":"121","author":"Castillo","year":"2015","journal-title":"Cancer"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative disorders: implications for targeted therapyAP-1 activity and EBV infection induce PD-L1","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.3390\/cancers13174366","article-title":"Hodgkin lymphoma in people living with HIV","volume":"13","author":"Navarro","year":"2021","journal-title":"Cancers"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/jnci\/djm010","article-title":"HIV\/AIDS cancer match study. AIDS-related cancer and severity of immunosuppression in persons with AIDS","volume":"99","author":"Biggar","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/annonc\/mdf239","article-title":"Hodgkin\u2019s disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony-stimulating factor","volume":"13","author":"Gastaldi","year":"2002","journal-title":"Ann Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/00126334-200008150-00009","article-title":"Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin\u2019s disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149)","volume":"24","author":"Levine","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3816\/CLM.2007.n.014","article-title":"Hodgkin lymphoma among patients infected with HIV in post-HAART era","volume":"7","author":"Tanaka","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/annonc\/mdg408","article-title":"BEACOPP therapeutic regimen for patients with Hodgkin\u2019s disease and HIV infection","volume":"14","author":"Hartmann","year":"2003","journal-title":"Ann Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/QAI.0b013e31815e722b","article-title":"Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy","volume":"47","author":"Berenguer","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3324\/haematol.10479","article-title":"Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin\u2019s lymphoma","volume":"92","author":"Xicoy","year":"2007","journal-title":"Haematologica"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/annonc\/mdl063","article-title":"Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin\u2019s disease: results of a multicenter study","volume":"17","author":"Hentrich","year":"2006","journal-title":"Ann Oncol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"iii70","DOI":"10.1093\/annonc\/mdu181","article-title":"Hodgkin\u2019s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Eichenauer","year":"2014","journal-title":"Ann Oncol"},{"key":"R21-20250504","first-page":"1226","article-title":"How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus","volume":"125","author":"Uldrick","year":"2015","journal-title":"Blood J Am Soc Hematol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan \u2013 a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"Grade guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"309","DOI":"10.7326\/0003-4819-117-4-309","article-title":"Increased incidence of Hodgkin disease in homosexual men with HIV infection","volume":"117","author":"Hessol","year":"1992","journal-title":"Ann Intern Med"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/QAD.0000000000000986","article-title":"Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy","volume":"30","author":"Olszewski","year":"2016","journal-title":"AIDS"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2012.41.8137","article-title":"Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study","volume":"30","author":"Hentrich","year":"2012","journal-title":"J Clin Oncol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"e22408","DOI":"10.1097\/MD.0000000000022408","article-title":"Clinical characteristics and outcomes of HIV positive patients with lymphoma in an oncological reference center in Mexico City","volume":"99","author":"Cardenas-Ortega","year":"2020","journal-title":"Medicine"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"578163","DOI":"10.1155\/2011\/578163","article-title":"Human immunodeficiency virus infection and Hodgkin\u2019s lymphoma in South Africa: an emerging problem","volume":"2011","author":"Patel","year":"2011","journal-title":"Adv Hematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:14:56Z","timestamp":1746335696000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":28,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030765","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,9,30]]}}}